Tech Company Financing Transactions
HealthTell Funding Round
On 3/10/2016, HealthTell secured $26.1 million in Series B financing from Third Point, Paladin Capital Group and private investors.
Transaction Overview
Company Name
Announced On
3/10/2016
Transaction Type
Venture Equity
Venture Equity
Venture Equity
Amount
$26,098,829
Round
Series B
Investors
Third Point (Lead Investor) (Jason Hong)
Paladin Capital Group (Paul Conley)
Proceeds Purpose
The Series B funding will allow the company to begin commercializing panels of tests for autoimmune diseases, such as lupus.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2420 Camino Ramon 125
San Ramon, CA 94583
USA
San Ramon, CA 94583
USA
Phone
Website
Email Address
Overview
The core of HealthTell's diagnostic platform are Antibodies. Our technology produces an Immunosignature: a real time, disease specific health status--all from a single drop of blood.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Colston
Chief Information Officer
Donald Morris
VP - Bus. Development
Isaac Bright
VP - Bus. Development
Glen Ferguson
VP - Finance
Myla Puyat
VP - Operations
David Smith
VP - Product Management
Ted Tarasow
VP - R & D
Kathryn Sykes
VP - Regulatory Affairs
Gary Riordan
Browse more venture capital transactions:
Prev: 3/10/2016: WeWork venture capital transaction
Next: 3/11/2016: Monscierge venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs